Evidence map›Paper›PMID 39558298›Full record

ArticleBMC ophthalmology2024

The analysis of foveal microvascular anomalies in retinopathy of prematurity after anti-vascular endothelial growth factor therapy using optical coherence tomography angiography.

Wenbo Liu, Lili Guo, Yi Cai, Hua Xu, Dandan Linghu, Xuemei Zhu, Yong Cheng, Xun Deng, Mingwei Zhao, Xuan Shi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenbo Liu *Department of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Lili Guo *Department of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Yi Cai *Department of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Hua XuDepartment of Ophthalmology, Children's Hospital of SooChow University, Suzhou, China.
Dandan LinghuDepartment of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Xuemei ZhuDepartment of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Yong ChengDepartment of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Xun DengDepartment of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Mingwei ZhaoDepartment of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
Xuan ShiDepartment of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China. drxuanshi@outlook.com.
Jianhong LiangDepartment of Ophthalmology, Peking University People's Hospital, Eye Disease and Optometry Institute, Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, College of Optometry, Peking University Health Science Center, No. 11 Xizhimen South Street, Xicheng District, Beijing, China. drljianhong@126.com.

Funding

the National Key R&D Program of China No. 2020YFC2008200the National Natural Science Foundation of China Grant No. 81970815
6 · The paper itself

Abstract

backgroundTo investigate the quantitative vascular and structural differences in the foveal region of the eyes in retinopathy of prematurity children with or without anti-vascular endothelial growth factor (VEGF) therapy and healthy children using optical coherence tomography angiography (OCTA).

methodsThis cross-sectional study analyzed 75 eyes from 44 subjects, categorized into four groups: ROP children treated with Conbercept or Ranibizumab, spontaneously regressed ROP, and healthy age-matched children. Using spectral-domain OCT and OCTA, we assessed parameters like central foveal thickness (CFT), foveal avascular zone (FAZ), superficial/deep capillary plexus (SCP/DCP), and choroidal vessel density (VD) at the fovea. Correlations between foveal microvasculature, preterm status and visual acuity were evaluated.

resultsSignificant differences were found in FAZ area, CFT, and VD-SCP (parafoveal) among the groups. The FAZ area was smaller in ROP children (with/without treatment) than in healthy counterparts(p = 0.009). CFT was higher in the Ranibizumab and spontaneously regressed groups compared to healthy ones (p = 0.043, p = 0.037), while Conbercept-treated children showed no significant difference (p = 0.886). Foveal VD trends were higher in groups A, B, and C compared to group D. FAZ area correlated negatively with CFT, VD-SCP (foveal), and VD-DCP (foveal) (p < 0.001, p < 0.001, p = 0.001), and positively with choroidal VD (p = 0.012). CFT showed positive correlations with VD-SCP (foveal) and VD-DCP (foveal) (p = 0.003, p = 0.001).

conclusionROP children exhibit a smaller FAZ area compared to healthy group, with no significant difference noted when comparing the use of different anti-VEGF agents. ROP children have a thicker CFT than healthy children, except for those treated with Conbercept. Furthermore, microvascular irregularities were correlated with central foveal thickness.

Indexed as

Angiogenesis InhibitorsFovea CentralisRanibizumabRetinopathy of PrematurityVascular Endothelial Growth Factor AAngiographyChildChild, PreschoolCross-Sectional StudiesFemaleHumansMaleRecombinant Fusion ProteinsRemission, SpontaneousRetrospective StudiesTomography, Optical CoherenceAngiogenesis InhibitorsKH902 fusion proteinRanibizumabRecombinant Fusion ProteinsVascular Endothelial Growth Factor AAnti-vascular endothelial growth factorCentral foveal thicknessFoveal avascular zoneOptical coherent tomography angiographyRetinopathy of prematuritySuperficial/deep capillary plexus

Identifiers

PMID39558298
PMCPMC11575202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.